Lv1
10 积分 2024-10-16 加入
Abstract 2383: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab
3小时前
求助中
TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review
7个月前
已完结
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
7个月前
已完结